Wall Street analyst estimates for Elicio Therapeutics, Inc. (ELTX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 0.33 |
Valuation Ratios
| Price / Book | 3.91 |
| EV / EBITDA | -0.90 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $6.6M | $4.0M | $1.5M | $2.9M | $28.3M | 0 | 0 | 0 | 0 |
| Cost of Revenue | $3.7M | $3.2M | $380000 | $1.1M | $1.8M | $1.2M | $1.1M | $1.2M | $1.2M | $1.1M |
| Gross Profit | $3.6M | $3.4M | $3.6M | $351000 | $1.1M | $27.1M | -$1.1M | -$1.2M | -$1.2M | -$1.1M |
| Research & Development | 0 | $196008 | $9.2M | $29.8M | $38.9M | $48.6M | $17.0M | $22.7M | $33.7M | $24.9M |
| Selling, General & Admin | $4.0M | $3.6M | $8.8M | $9.2M | $17.5M | $17.8M | $5.6M | $11.9M | $11.3M | $12.8M |
| Operating Expenses | $4.0M | $3.8M | $18.0M | $38.9M | $56.3M | $66.4M | $22.7M | $34.6M | $43.8M | $36.6M |
| Operating Income | -$419220 | -$397800 | -$14.3M | -$38.6M | -$55.3M | -$39.3M | -$23.7M | -$35.7M | -$45.0M | -$37.7M |
| EBITDA | $2.0M | $62540 | -$14.3M | -$40.2M | -$70.6M | -$51.9M | -$23.6M | -$33.0M | -$50.3M | -$37.3M |
| Interest Expense | $307450 | $300432 | 0 | 0 | $8.8M | $876442 | $3.6M | $1.1M | $455000 | $1.1M |
| Pre-tax Income | $1.2M | $1.7M | -$20.0M | -$40.7M | -$80.1M | -$54.6M | -$28.2M | -$35.2M | -$51.9M | -$39.6M |
| Income Tax | $201858 | $452778 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | $307303 | $632241 | -$20.0M | -$40.7M | -$80.1M | -$26.4M | -$28.2M | -$35.2M | -$51.9M | -$39.6M |
| EPS | $50.21 | $103.31 | $-6.79 | $-1.50 | $-1.93 | $-19.32 | $-9.10 | $-6.96 | $-4.25 | $-2.58 |
| EPS (Diluted) | $50.21 | $103.31 | $-6.79 | $-1.50 | $-1.93 | $-19.32 | $-9.10 | $-6.96 | $-4.25 | $-2.58 |
| Shares Outstanding (Diluted) | $6120 | $6120 | $2.9M | $8.2M | $8.2M | $3.2M | $3.1M | $5.1M | $12.2M | $15.3M |
Price
| Price | $1.77 |
| Market Cap | $34M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACTU · APLT · CRBP · CRDF · MIST · MOLN · NKTX
Explore sector: Healthcare · Biotechnology
More sections of ELTX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks